Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: licogliflozin, sotagliflozin | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 210 | 0.85 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 7742
Sealed predictions
- SLC5A1 in dopamine neurons, braak+0.42 (p 0.258) → +0.34 (p 0.367)receipt 7749
Swarm cases
receipt 7749: SLC5A1 in dopamine neurons, braak
- power
- full sample +0.36 (p 0.142, n 18), 95% CI -0.13 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.38 (p 0.120, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.30 (p 0.225, n 18). could be the mix.
- skeptic
- leave-one-out range +0.28 to +0.48, sign flips 0; without severely affected donors +0.36 (p 0.142, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC5A1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts